drugset / Trial / NCT02704390

Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

NCT02704390

Phase 3 Completed 64 enrolled Orient Pharma Co., Ltd. Durect · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.

Timeline

Start
2016-01
Primary completion
2019-08
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 22 mg Oral
Subject Methylphenidate Small molecule 33 mg Oral
Subject Methylphenidate Small molecule 44 mg Oral